Clinical Trials Browser

INDUSTRY × Lymphoma, Large B-Cell, Diffuse × Lenalidomide × Clear all

NCT05283720 2026-04-13

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-04-08

EPCORE DLBCL-3

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-04-08

EPCORE DLBCL-4

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04824092 2026-04-01

frontMIND

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04903197 2026-04-01

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1 Terminated

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT05222555 2026-01-16

MINDway

Phase 1/2 Active not recruiting

53 enrolled 14 charts

Lymphoma, Large B-Cell, Diffuse

NCT04661007 2025-12-18

J-MIND

Phase 1/2 Active not recruiting

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05429268 2025-12-10

firmMIND

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05626322 2025-09-05

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Phase 1/2 Terminated

6 enrolled 17 charts

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05265975 2025-06-09

SWATCH

Phase 1/2 Terminated

Lymphoma, Large B-Cell, Diffuse

NCT04436107 2025-05-23

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Completed

66 enrolled 52 charts

Lymphoma, Large B-Cell, Diffuse

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02600897 2023-12-26

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Completed

114 enrolled 34 charts

Lymphoma, Follicular, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02733042 2023-11-18

FUSION NHL 001

Phase 1/2 Completed

106 enrolled 48 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 3 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02285062 2023-06-22

ROBUST

Phase 3 Completed

570 enrolled 27 charts

Limb-girdle muscular dystrophy, type 2C, Lymphoma, Large B-Cell, Diffuse

NCT03003520 2023-05-22

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase 2 Completed

46 enrolled 20 charts

LymphoidSarcoma

Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT02077166 2022-02-04

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1/2 Completed

138 enrolled 22 charts

Lymphoma, Large B-Cell, Diffuse

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT01197560 2019-11-25

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2/3 Completed

111 enrolled 20 charts

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT00474188 2009-09-02

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Terminated

26 enrolled 5 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse